Tesaro Scores $101M In A Second Round Of Funding
This article was originally published in The Pink Sheet Daily
Executive Summary
The Boston biotech has plans to use its Series B financing to fund its current research, as well as invest in other assets to flesh out its pipeline.
You may also be interested in...
Flush With Cash, Tesaro Advances Rolapitant Toward NDA
Tesaro’s three-drug oncology program, including its lead NK-1 product for chemo-induced nausea and vomiting, is boosted by a recent raise from the public markets.
Eisai Surprise Winner in MGI Auction
Everyone knew that MGI Pharma was up for sale, but few expected mid-cap Japanese firm Eisai to emerge victorious. Eisai pushed its offer up to $41-per-share, all cash, even though there was only one other, non-definitive, offer on the table. The $3.3 billion deal nabs Eisai two records: the largest foreign acquisition by any Japanese pharma, and the year's largest specialty pharma purchase.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.